{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:23:00Z","timestamp":1791091380863,"version":"4.1.0"},"reference-count":35,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:p>OBJECTIVE: We hypothesized that higher cumulative doses of recombinant erythropoietin (rEPO) for extremely preterm infants during the first 6 postnatal weeks would improve developmental outcomes, as evidenced in evaluations with the Bayley Scales of Infant Development-II Revised.<\/jats:p>\n               <jats:p>METHODS: This was a retrospective cohort study with a data set for a group (N = 366) of infants of &amp;lt;1500 g and \u226430 weeks of gestation that was created initially to examine the association between rEPO treatment and retinopathy of prematurity. Infants who underwent developmental follow-up evaluations at corrected age of &amp;gt;12 months were included. The associations between rEPO doses and higher Bayley Scales of Infant Development Psychomotor Developmental Index and Mental Developmental Index (MDI) scores were estimated in multivariate linear regression analyses.<\/jats:p>\n               <jats:p>RESULTS: Eighty-two infants underwent developmental evaluations after 12 months. The median age of evaluation was 25 months. The median 6-week cumulative rEPO dose was 3750 U\/kg. In multivariate analyses, Psychomotor Developmental Index (PDI) scores were associated with transfusions, female gender, birth weight, and 5-minute Apgar scores (R2 = 0.39). MDI scores were associated with 6-week rEPO dose, female gender, prenatal steroid treatment for \u226548 hours, and breast milk feedings (R2 = 0.40).<\/jats:p>\n               <jats:p>CONCLUSIONS: These findings identify a dose-response relationship between rEPO treatment and improved MDI scores. They are consistent with findings of adult studies and animal brain injury models and await confirmation.<\/jats:p>","DOI":"10.1542\/peds.2008-2701","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T11:32:40Z","timestamp":1254137560000},"page":"e681-e687","source":"Crossref","is-referenced-by-count":68,"title":["Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm Infants"],"prefix":"10.1542","volume":"124","author":[{"given":"Mark S.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Eastern Maine Medical Center, Bangor, Maine; and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Eichorst","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"LaLa-Black","sequence":"additional","affiliation":[{"name":"Rehabilitation Services, Presbyterian\/St Luke's Medical Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Rehabilitation Services, Presbyterian\/St Luke's Medical Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"2021120905070231600_R1","doi-asserted-by":"crossref","unstructured":"Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci.\u20081996;8(4):666\u2013676","DOI":"10.1111\/j.1460-9568.1996.tb01252.x"},{"key":"2021120905070231600_R2","doi-asserted-by":"crossref","unstructured":"Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A.\u20081995;92(9):3717\u20133720","DOI":"10.1073\/pnas.92.9.3717"},{"key":"2021120905070231600_R3","doi-asserted-by":"crossref","unstructured":"Dame C, Bartmann P, Wolber E, Fahnenstich H, Hofmann D, Fandrey J. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res.\u20082000;125(1\u20132):69\u201374","DOI":"10.1016\/S0165-3806(00)00118-8"},{"key":"2021120905070231600_R4","doi-asserted-by":"crossref","unstructured":"Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol.\u20081999;2(2):148\u2013158","DOI":"10.1007\/s100249900103"},{"key":"2021120905070231600_R5","doi-asserted-by":"crossref","unstructured":"Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res.\u20081998;43(1):40\u201349","DOI":"10.1203\/00006450-199801000-00007"},{"key":"2021120905070231600_R6","doi-asserted-by":"crossref","unstructured":"Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development.\u20082002;129(2):505\u2013516","DOI":"10.1242\/dev.129.2.505"},{"key":"2021120905070231600_R7","doi-asserted-by":"crossref","unstructured":"Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res.\u20081996;40(3):376\u2013380","DOI":"10.1203\/00006450-199609000-00002"},{"key":"2021120905070231600_R8","doi-asserted-by":"crossref","unstructured":"Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant.\u20082002;17(suppl 1):8\u201312","DOI":"10.1093\/ndt\/17.suppl_1.8"},{"key":"2021120905070231600_R9","doi-asserted-by":"crossref","unstructured":"Sadamoto Y, Igase K, Sakanaka M, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun.\u20081998;253(1):26\u201332","DOI":"10.1006\/bbrc.1998.9748"},{"key":"2021120905070231600_R10","doi-asserted-by":"crossref","unstructured":"Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab.\u20081999;19(6):643\u2013651","DOI":"10.1097\/00004647-199906000-00007"},{"key":"2021120905070231600_R11","doi-asserted-by":"crossref","unstructured":"Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A.\u20081998;95(8):4635\u20134640","DOI":"10.1073\/pnas.95.8.4635"},{"key":"2021120905070231600_R12","doi-asserted-by":"crossref","unstructured":"Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res.\u20082005;57(4):481\u2013487","DOI":"10.1203\/01.PDR.0000155760.88664.06"},{"key":"2021120905070231600_R13","doi-asserted-by":"crossref","unstructured":"Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res.\u20082005;58(2):297\u2013301","DOI":"10.1203\/01.PDR.0000169971.64558.5A"},{"key":"2021120905070231600_R14","doi-asserted-by":"crossref","unstructured":"Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience.\u20081997;76(1):105\u2013116","DOI":"10.1016\/S0306-4522(96)00306-5"},{"key":"2021120905070231600_R15","doi-asserted-by":"crossref","unstructured":"Wen TC, Sadamoto Y, Tanaka J, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res.\u20082002;67(6):795\u2013803","DOI":"10.1002\/jnr.10166"},{"key":"2021120905070231600_R16","doi-asserted-by":"crossref","unstructured":"Calapai G, Marciano MC, Corica F, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol.\u20082000;401(3):349\u2013356","DOI":"10.1016\/S0014-2999(00)00466-0"},{"key":"2021120905070231600_R17","doi-asserted-by":"crossref","unstructured":"Kumral A, Baskin H, Gokmen N, et al. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin?Biol Neonate.\u20082004;85(1):51\u201354","DOI":"10.1159\/000074958"},{"key":"2021120905070231600_R18","doi-asserted-by":"crossref","unstructured":"Sire\u0301n AL, Knerlich F, Poser W, Gleiter CH, Bru\u0308ck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic\/hypoxic brain. Acta Neuropathol.\u20082001;101(3):271\u2013276","DOI":"10.1007\/s004010000297"},{"key":"2021120905070231600_R19","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med.\u20082002;8(8):495\u2013505","DOI":"10.1007\/BF03402029"},{"key":"2021120905070231600_R20","doi-asserted-by":"crossref","unstructured":"Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke.\u20082004;35(7):1732\u20131737","DOI":"10.1161\/01.STR.0000132196.49028.a4"},{"key":"2021120905070231600_R21","doi-asserted-by":"crossref","unstructured":"Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I\/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics.\u20082008;122(2):383\u2013391","DOI":"10.1542\/peds.2007-2711"},{"key":"2021120905070231600_R22","doi-asserted-by":"crossref","unstructured":"Fauche\u0300re JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics.\u20082008;122(2):375\u2013382","DOI":"10.1542\/peds.2007-2591"},{"key":"2021120905070231600_R23","doi-asserted-by":"crossref","unstructured":"Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol.\u20081999;19(6):403\u2013406","DOI":"10.1038\/sj.jp.7200244"},{"key":"2021120905070231600_R24","doi-asserted-by":"crossref","unstructured":"Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics.\u20082004;114(5):1287\u20131291","DOI":"10.1542\/peds.2003-1129-L"},{"key":"2021120905070231600_R25","doi-asserted-by":"crossref","unstructured":"Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics.\u20082006;118(3). Available at: www.pediatrics.org\/cgi\/content\/full\/118\/3\/e635","DOI":"10.1542\/peds.2005-3186"},{"key":"2021120905070231600_R26","doi-asserted-by":"crossref","unstructured":"Strunk T, Hartel C, Schultz C. Does erythropoietin protect the preterm brain?Arch Dis Child Fetal Neonatal Ed.\u20082004;89(4):F364\u2013F366","DOI":"10.1136\/adc.2003.041533"},{"key":"2021120905070231600_R27","doi-asserted-by":"crossref","unstructured":"Dame C, Fahnenstich H. Don't give up on erythropoietin as a neuroprotective agent. Pediatrics.\u20082005;116(2):521\u2013522","DOI":"10.1542\/peds.2005-0637"},{"key":"2021120905070231600_R28","doi-asserted-by":"crossref","unstructured":"Sola A, Wen TC, Hamrick SE, Ferriero DM. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?Pediatr Res.\u20082005;57(5):110R\u2013117R","DOI":"10.1203\/01.PDR.0000159571.50758.39"},{"key":"2021120905070231600_R29","doi-asserted-by":"crossref","unstructured":"Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl.\u20082002;91(438):36\u201342","DOI":"10.1111\/j.1651-2227.2002.tb02904.x"},{"key":"2021120905070231600_R30","doi-asserted-by":"crossref","unstructured":"Brown MS, Baron AE, France EK, Hamman RF. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J AAPOS.\u20082006;10(2):143\u2013149","DOI":"10.1016\/j.jaapos.2005.09.005"},{"key":"2021120905070231600_R31","doi-asserted-by":"crossref","unstructured":"Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A.\u20082002;99(16):10659\u201310664","DOI":"10.1073\/pnas.152321399"},{"key":"2021120905070231600_R32","doi-asserted-by":"crossref","unstructured":"Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med.\u20082002;8(7):718\u2013724","DOI":"10.1038\/nm723"},{"key":"2021120905070231600_R33","doi-asserted-by":"crossref","unstructured":"Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993\u20131994. Pediatrics.\u20082000;105(6):1216\u20131226","DOI":"10.1542\/peds.105.6.1216"},{"key":"2021120905070231600_R34","doi-asserted-by":"crossref","unstructured":"McGrath E, Wypij D, Rappaport LA, Newburger JW, Bellinger DC. Prediction of IQ and achievement at age 8 years from neurodevelopmental status at age 1 year in children with D-transposition of the great arteries. Pediatrics.\u20082004;114(5). Available at: www.pediatrics.org\/cgi\/content\/full\/114\/5\/e572","DOI":"10.1542\/peds.2003-0983-L"},{"key":"2021120905070231600_R35","doi-asserted-by":"crossref","unstructured":"Aylward GP. Methodological issues in outcome studies of at-risk infants. J Pediatr Psychol.\u20082002;27(1):37\u201345","DOI":"10.1093\/jpepsy\/27.1.37"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/4\/e681\/1012021\/zpe0100900e681.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/4\/e681\/1012021\/zpe0100900e681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T22:22:00Z","timestamp":1639088520000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/4\/e681\/71864\/Higher-Cumulative-Doses-of-Erythropoietin-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,10,1]]},"published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-2701","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,1]]}}}